JP2015529652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529652A5 JP2015529652A5 JP2015524600A JP2015524600A JP2015529652A5 JP 2015529652 A5 JP2015529652 A5 JP 2015529652A5 JP 2015524600 A JP2015524600 A JP 2015524600A JP 2015524600 A JP2015524600 A JP 2015524600A JP 2015529652 A5 JP2015529652 A5 JP 2015529652A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aryl
- deuterium
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(**1)=C(*2**(C)CCC(C)CCC3**CC2)C3=C1C(C)C(C)C Chemical compound CCC(**1)=C(*2**(C)CCC(C)CCC3**CC2)C3=C1C(C)C(C)C 0.000 description 5
- YIINKKNBXUALQJ-CPPUAGTESA-N CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(c2c3C4NC2CC(C)C4)ccc3-c(cc2)ccc2-c(cc2)cc3c2nc(C(CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(c2c3C4NC2CC(C)C4)ccc3-c(cc2)ccc2-c(cc2)cc3c2nc(C(CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O YIINKKNBXUALQJ-CPPUAGTESA-N 0.000 description 1
- LQKWQBFFAXGZOK-WPZYDENFSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)c(C(C3)N4C3(C)CC43)c3c2-c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)c(C(C3)N4C3(C)CC43)c3c2-c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O LQKWQBFFAXGZOK-WPZYDENFSA-N 0.000 description 1
- JWJIPZPFNNVDPQ-BSDZSUBPSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)c(C3N(C4C5)C5(C)C3)c4c2-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)c(C3N(C4C5)C5(C)C3)c4c2-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O JWJIPZPFNNVDPQ-BSDZSUBPSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210273491 | 2012-08-03 | ||
| CN201210273491.8 | 2012-08-03 | ||
| CN201310116933 | 2013-04-03 | ||
| CN201310116933.2 | 2013-04-03 | ||
| PCT/CN2013/000915 WO2014019344A1 (en) | 2012-08-03 | 2013-08-05 | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529652A JP2015529652A (ja) | 2015-10-08 |
| JP2015529652A5 true JP2015529652A5 (enExample) | 2016-09-23 |
Family
ID=50027184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524600A Pending JP2015529652A (ja) | 2012-08-03 | 2013-08-05 | Ｃ型肝炎阻害剤である架橋環化合物及びその医薬品への応用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9309231B2 (enExample) |
| EP (1) | EP2880030B1 (enExample) |
| JP (1) | JP2015529652A (enExample) |
| KR (1) | KR20150039200A (enExample) |
| CN (1) | CN103570693B (enExample) |
| AU (1) | AU2013299246B2 (enExample) |
| BR (1) | BR112015000420A2 (enExample) |
| CA (1) | CA2872118A1 (enExample) |
| MX (1) | MX2015001571A (enExample) |
| MY (1) | MY187617A (enExample) |
| RU (1) | RU2015107043A (enExample) |
| SG (1) | SG11201406824XA (enExample) |
| TW (1) | TWI610916B (enExample) |
| WO (1) | WO2014019344A1 (enExample) |
| ZA (1) | ZA201407779B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201412709A (zh) | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2929858C (en) | 2013-11-22 | 2022-03-29 | CL BioSciences LLC | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
| US9738629B2 (en) | 2014-01-23 | 2017-08-22 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| CN107954997A (zh) * | 2014-02-21 | 2018-04-24 | 常州寅盛药业有限公司 | 作为丙肝病毒抑制剂的联环化合物 |
| CN105384792B (zh) * | 2014-08-23 | 2020-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016095814A1 (en) * | 2014-12-16 | 2016-06-23 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors and preparation thereof |
| CN105968101B (zh) * | 2015-03-12 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| JP7012924B2 (ja) * | 2017-03-02 | 2022-02-15 | ウォックハート リミテッド | 抗菌化合物としての複素環誘導体 |
| WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
| WO2020112357A1 (en) * | 2018-11-28 | 2020-06-04 | The Regents Of The University Of Michigan | Succinate dehydrogenase inhibitors and methods of making and using the same |
| US20220227729A1 (en) | 2019-05-21 | 2022-07-21 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| CN111118073B (zh) * | 2019-12-27 | 2022-02-15 | 宜昌东阳光生化制药有限公司 | 酶法合成依米他韦中间体的方法 |
| KR20220123404A (ko) * | 2020-01-03 | 2022-09-06 | 블루 오크 파마슈티컬스, 인코포레이티드 | Cns 장애를 치료하기 위한 화합물 및 조성물 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| GB202013383D0 (en) * | 2020-08-26 | 2020-10-07 | Givaudan Sa | Process |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3019259A (en) * | 1959-11-02 | 1962-01-30 | Dow Chemical Co | 1, 4-dihydro-1, 4-methanonaphthalene-5, 8-diamine |
| US3268581A (en) * | 1964-05-08 | 1966-08-23 | Dow Chemical Co | Anthraquinone dialkanesulfonimide |
| US3493616A (en) * | 1967-02-27 | 1970-02-03 | Universal Oil Prod Co | Hydroxy and/or hydrocarbyloxy and amino-alkano-tetrahydronaphthalenes |
| US3835104A (en) * | 1968-09-05 | 1974-09-10 | Snam Progetti | Curable,amorphous,olefinic terpolymers from alphamono olefins and polyenes |
| US4009200A (en) * | 1973-02-02 | 1977-02-22 | Uniroyal, Inc. | Hexahalo-1,4-dihydro-1,4-methano-napth-5,8-ylene acetates |
| JPS60152435A (ja) * | 1984-01-20 | 1985-08-10 | Dainippon Ink & Chem Inc | ２，３−ジアセチルノルボルナジエンとその製造法 |
| US7291689B1 (en) * | 2006-05-01 | 2007-11-06 | Seoul National University Industry Foundation | Thermally stable low dielectric norbornene polymers with improved solubility and adhesion property |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BRPI0922366B8 (pt) * | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
| EP2774927A1 (en) | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8637561B2 (en) | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
| ES2606717T3 (es) * | 2009-02-27 | 2017-03-27 | Enanta Pharmaceuticals, Inc. | Inhibidores del virus de la hepatitis C |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| CN102427729B (zh) | 2009-03-27 | 2014-09-03 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9139569B2 (en) | 2009-05-12 | 2015-09-22 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| RS56654B8 (sr) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
| KR101724765B1 (ko) | 2009-05-18 | 2017-04-07 | 액테리온 파마슈티칼 리미티드 | Ａｌｘ 수용체 및/또는 ｆｐｒｌ2 아고니스트로서의 브릿지 스피로［2.4］헵탄 유도체 |
| US8772505B2 (en) * | 2009-05-29 | 2014-07-08 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8221737B2 (en) * | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| AU2010324871A1 (en) | 2009-11-25 | 2012-06-14 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| SG181797A1 (en) | 2009-12-18 | 2012-07-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| US20130072523A1 (en) | 2009-12-24 | 2013-03-21 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| WO2011119870A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
| TW201201801A (en) | 2010-06-09 | 2012-01-16 | Presidio Pharmaceuticals Inc | Inhibitors of HCV NS5A protein |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012003642A1 (en) | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| WO2012013643A1 (en) | 2010-07-26 | 2012-02-02 | Tibotec Pharmaceuticals | Hetero-bicyclic derivatives as hcv inhibitors |
| WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| DK2599774T3 (en) * | 2010-07-29 | 2016-10-24 | Astellas Pharma Inc | DEHYDRATED pyridine AS CB2 cannabinoid receptor ligands |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
| BR112013007696A2 (pt) | 2010-09-29 | 2019-09-24 | Merck Sharp & Dohme | composto, composição farmacêutica, usos do referido composto e da referida composição |
| WO2012040924A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
| WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| WO2012041227A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds for treating hepatitis c viral infection |
| US20150158909A1 (en) | 2010-12-15 | 2015-06-11 | Abbevie Inc. | Anti-viral compounds |
| WO2012083053A2 (en) | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| MX2013006828A (es) | 2010-12-16 | 2014-10-14 | Abbvie Inc | Compuestos antivirales. |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| CA2841095A1 (en) * | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| PH12014500311A1 (en) | 2011-08-08 | 2014-03-31 | Lupin Ltd | Antiviral compounds with a fused tricyclic ring |
| WO2013022810A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Chemical compounds |
-
2013
- 2013-08-02 TW TW102127866A patent/TWI610916B/zh active
- 2013-08-05 EP EP13824843.0A patent/EP2880030B1/en not_active Not-in-force
- 2013-08-05 AU AU2013299246A patent/AU2013299246B2/en not_active Ceased
- 2013-08-05 JP JP2015524600A patent/JP2015529652A/ja active Pending
- 2013-08-05 KR KR20157002654A patent/KR20150039200A/ko not_active Withdrawn
- 2013-08-05 SG SG11201406824XA patent/SG11201406824XA/en unknown
- 2013-08-05 WO PCT/CN2013/000915 patent/WO2014019344A1/en not_active Ceased
- 2013-08-05 US US14/397,200 patent/US9309231B2/en not_active Expired - Fee Related
- 2013-08-05 MX MX2015001571A patent/MX2015001571A/es unknown
- 2013-08-05 RU RU2015107043A patent/RU2015107043A/ru not_active Application Discontinuation
- 2013-08-05 BR BR112015000420A patent/BR112015000420A2/pt not_active IP Right Cessation
- 2013-08-05 CA CA2872118A patent/CA2872118A1/en not_active Abandoned
- 2013-08-05 MY MYPI2014703257A patent/MY187617A/en unknown
- 2013-08-05 CN CN201310337556.5A patent/CN103570693B/zh active Active
-
2014
- 2014-10-24 ZA ZA2014/07779A patent/ZA201407779B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130072528A1 (en) | Methods for Treating HCV | |
| RU2015107043A (ru) | Соединенные циклические соединения как ингибиторы вируса гепатита с (вгс) и их фармацевтическое применение | |
| AU2022209336A1 (en) | Methods for treating HCV | |
| EP2968302B9 (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| US20130172240A1 (en) | Methods for treating hcv | |
| JP2013535487A5 (enExample) | ||
| WO2016134054A1 (en) | Anti-viral compounds | |
| EP2416765B1 (en) | Hcv inhibitor and therapeutic agent combinations | |
| US20140024613A1 (en) | Methods for Treating HCV | |
| US20160317603A9 (en) | Methods for Treating HCV | |
| WO2016134056A1 (en) | Anti-viral compounds | |
| WO2017040892A1 (en) | Anti-viral compounds | |
| WO2016182935A1 (en) | Anti-viral compounds | |
| WO2016134057A1 (en) | Anti-viral compounds | |
| WO2016182936A1 (en) | Anti-viral compounds | |
| US20180042982A1 (en) | Methods for Treating HCV | |
| WO2019074507A1 (en) | METHODS FOR THE TREATMENT OF HCV | |
| WO2019046569A1 (en) | METHODS FOR THE TREATMENT OF HCV | |
| WO2019027694A1 (en) | METHODS OF TREATING HCV | |
| WO2016182938A1 (en) | Anti-viral compounds |